
Sign up to save your podcasts
Or


Ira Jersey, Chief US interest rate strategist for Bloomberg Intelligence, discusses how Treasuries might react to a government shutdown on Friday. Michael Shah, Pharma Analyst with Bloomberg Intelligence, joins to discuss Novo Nordisk, Ozempic, and the weight loss drug push. Jake Saper, Emergence Capital General Partner, joins to talk about investment strategies, tech, and markets. Jereme Sylvain, CFO at DexCom (NASDAQ: DXCM), joins to discuss company earnings, its initiatives in healthcare and specifically for diabetes, and outlook for the firm and industry. Hosted by Paul Sweeney and Matt Miller.
See omnystudio.com/listener for privacy information.
By Bloomberg3.8
381381 ratings
Ira Jersey, Chief US interest rate strategist for Bloomberg Intelligence, discusses how Treasuries might react to a government shutdown on Friday. Michael Shah, Pharma Analyst with Bloomberg Intelligence, joins to discuss Novo Nordisk, Ozempic, and the weight loss drug push. Jake Saper, Emergence Capital General Partner, joins to talk about investment strategies, tech, and markets. Jereme Sylvain, CFO at DexCom (NASDAQ: DXCM), joins to discuss company earnings, its initiatives in healthcare and specifically for diabetes, and outlook for the firm and industry. Hosted by Paul Sweeney and Matt Miller.
See omnystudio.com/listener for privacy information.

958 Listeners

1,177 Listeners

2,180 Listeners

425 Listeners

969 Listeners

195 Listeners

1,047 Listeners

187 Listeners

64 Listeners

1,300 Listeners

63 Listeners

30 Listeners

64 Listeners

4 Listeners

58 Listeners

233 Listeners

229 Listeners

64 Listeners

88 Listeners

78 Listeners

81 Listeners

82 Listeners

396 Listeners

9 Listeners

19 Listeners

12 Listeners

7 Listeners

2 Listeners

114 Listeners

24 Listeners